Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00557310 · ClinicalTrials.gov registry record · Phase 4
A Study Using Imaging Technology to Measure Changes in Bone Structure After Treatment With Teriparatide
A Phase 4 study of Osteoporosis, Postmenopausal, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 35
- Enrollment target
- 6
- Study locations
NCT00557310: Completed Phase 4 study of Osteoporosis, Postmenopausal, sponsored by Eli Lilly and Company.
NCT00557310 is a Phase 4 study of Osteoporosis, Postmenopausal that has completed, run by Eli Lilly and Company. The registered enrollment target is 35 participants, below the 2,731-participant average among 12 other Osteoporosis, Postmenopausal trials with a reported enrollment target (99% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00557310, a Phase 4 study of Osteoporosis, Postmenopausal, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 35 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to use imaging technologies to demonstrate the effects of teriparatide on bone structure following 18 to 24 months of therapy in postmenopausal women with osteoporosis.
Primary Outcome
SCR is a measure of the computed ratio of plate-like to rod-like structures in a given volume of trabecular bone and reflects the integrity of the trabecular network. The higher the value for SCR, the more intact the trabecular network. Least squares (LS) mean of the percent change from baseline to 18 months is from a mixed model repeated measurements analysis. The model included terms for investigator site, prior bisphosphonate use, visit and baseline.
Conditions Studied
Interventions
- DRUG teriparatide
Study Locations (6)
Arizona
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Tucson
Colorado
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Lakewood
Nebraska
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Omaha
New Mexico
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Albuquerque
Pennsylvania
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Pittsburgh
British Columbia
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Vancouver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2007-11 |
| Est. Completion | 2011-05 |
| Phase | Phase 4 |
What the finished NCT00557310 record still lists
NCT00557310 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 2,731-participant average among 12 other Osteoporosis, Postmenopausal trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Osteoporosis, Postmenopausal appearing as the primary indexed condition, and to 1 intervention - of which teriparatide is the first listed.
NCT00557310 lists 6 locations in 6 states (Arizona, Colorado, Nebraska).
Frequently Asked Questions
What is clinical trial NCT00557310 about?
NCT00557310 is a clinical study titled "A Study Using Imaging Technology to Measure Changes in Bone Structure After Treatment With Teriparatide". The purpose of this study is to use imaging technologies to demonstrate the effects of teriparatide on bone structure following 18 to 24 months of therapy in postmenopausal women with osteoporosis.
What is the current status of trial NCT00557310?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 35 participants. The study started on 2007-11. Estimated completion is 2011-05.
What conditions does trial NCT00557310 study?
This clinical trial studies the following conditions: Osteoporosis, Postmenopausal.
What interventions are being tested in trial NCT00557310?
The interventions under investigation include: teriparatide (DRUG).
Who is sponsoring clinical trial NCT00557310?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00557310 being conducted?
This trial has 6 study locations across Arizona, Colorado, Nebraska, New Mexico, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoporosis, Postmenopausal
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00557310's enrollment target sits among peer trials
35 12th of 12 higher than 1 of 12 other Osteoporosis, Postmenopausal trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteoporosis, Postmenopausal trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Combined Anabolic Therapy
RECRUITING · Phase 4
-
Comparative Antiresorptive Efficacy Discontinuation of Denosumab
ACTIVE NOT RECRUITING · Phase 4
-
Romosozumab Use to Build Skeletal Integrity
ACTIVE NOT RECRUITING · Phase 4
-
Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone
ACTIVE NOT RECRUITING · Phase 4
-
Carotid Artery Intima-Media Thickness Following Exposure to Raloxifene or Placebo
COMPLETED · Phase 4
-
Effects of Teriparatide or Zoledronic Acid Treatment on Bone in Postmenopausal Osteoporotic Women
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia